^
Association details:
Biomarker:EGFR amplification
Cancer:Glioblastoma
Drug:erlotinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Excerpt:
...- Availability of paraffin blocks or slides to allow determination of EGFR amplification status...
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Excerpt:
For PFS...EGFR gene amplification was borderline significant for poor outcome in the entire study group (P = .048)...
DOI:
10.1200/JCO.2008.17.5984
Trial ID:
Evidence Level:
Resistant: C4 – Case Studies
Source:
Title:

Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review

Published date:
04/03/2022
Excerpt:
...although erlotinib and everolimus were given based on genetic test results, there was no response….There is no clear relationship between EGFR amplifications and survival in GBM. In our patient, we could not get a response from the erlotinib treatment given due to EGFR amplification.
DOI:
10.7759/cureus.23796
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

Excerpt:
On the whole, 13 treatments were Avatar directed, and in 11 the Avatar response mimicked the patient response, predicting 2 progressive disease, 1 complete response, 6 partial response, and 2 stable disease (Table 3).
DOI:
10.1158/1078-0432.CCR-13-3047